Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a two-drug cocktail in patients with MET-dysregulated advanced solid tumors: A phase I, multicenter, open-label, single-sequence drug-drug interaction study

Enrique Grande[1], Monica Giovannini[2], Eddie Marriere[3], Philippe Pultar[2], Michelle Quinlan[2], Xinhui Chen[2], Giuseppe Curigliano[4], and Xiaoming Cui[2]

[1]MD Anderson Cancer Center Madrid
[2]Novartis Pharmaceuticals Corp
[3]Novartis Pharma AG
[4]Istituto Europeo di Oncologia

July 21, 2020

Abstract

Aims Capmatinib, an orally bioavailable, highly potent and selective MET inhibitor, was recently approved to treat adult patients with metastatic non-small cell lung cancer with METex14 skipping mutations. The study investigated the effect of capmatinib on the pharmacokinetics of a single oral dose of digoxin and rosuvastatin, administered orally as a two-drug cocktail in patients with MET-dysregulated advanced solid tumors. Methods This was a multicenter, open-label, single-sequence study. An oral drug cocktail containing 0.25 mg digoxin and 10 mg rosuvastatin was administered to adult patients with MET-dysregulated advanced solid tumors on Day 1, and then on Day 22 with capmatinib. Between Days 11 and 32, capmatinib 400 mg was administered twice daily to ensure the attainment of steady state for drug-drug interaction (DDI) assessment. Pharmacokinetics of cocktail drugs and safety of capmatinib were evaluated. Results Thirty-two patients (median age: 61.5 years) were enrolled. Co-administration of capmatinib increased digoxin C_{max}, and AUC_{inf} by 74%, and 47%, respectively. Co-administration of capmatinib increased rosuvastatin C_{max}, and AUC_{inf} by 204%, and 108%, respectively. Most frequent adverse events (AEs; [?]25% for all grades) were nausea (56.3%), asthenia (43.8%), constipation and vomiting (40.6%, each), peripheral edema (28.1%) and pyrexia (25%). Most frequent Grade 3/4 AEs ([?]5%) were anemia and pulmonary embolism (9.4%, each), asthenia, dyspnea, nausea and vomiting (6.3%, each). Conclusion This study demonstrated that capmatinib is an inhibitor of P-gp as well as BCRP transporters, with clinically relevant DDI potential. Capmatinib was well-tolerated and no unexpected safety concerns were observed.

Title

Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a two-drug cocktail in patients with*MET* -dysregulated advanced solid tumors: A phase I, multicenter, open-label, single-sequence drug-drug interaction study

Authors

Enrique Grande[1], Monica Giovannini[2], Eddie Marriere[3], Philippe Pultar[2], Michelle Quinlan[2], Xinhui Chen[2], Giuseppe Curigliano[4,5], Xiaoming Cui[2]

Affiliations

[1]Medical Oncology Department, MD Anderson Cancer Center Madrid, Madrid, Spain; [2]Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;[3]Novartis Pharma AG, Basel, Switzerland;[4]Istituto Europeo di Oncologia, IRCCS, Milan, Italy;[5]University of Milano, Milan, Italy

Correspondence

Xiaoming Cui, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Email: xiaoming.cui@novartis.com

Telephone number: +18627781087

Principal Investigators

The authors confirm that Enrique Grande and Giuseppe Curigliano are the principal investigators for this paper and they had direct clinical responsibility for patients.

Running Title

Capmatinib DDI with digoxin and rosuvastatin

Word Count

- Abstract: 246 words (limit: 250 words)
- Manuscript: 3999 words (limit: 4000 words)
- Tables: 6/ Figures: 2

Statements

What is already known about this subject.

- Capmatinib is an orally bioavailable, highly potent and selective MET inhibitor with recent approval to treat adult patients with metastatic NSCLC with *METex14* skipping mutations.
- The pharmacokinetics of oral capmatinib has been characterized in multiple clinical trials previously.
- In vitro studies showed that capmatinib inhibits transporter -gp and BCRP.

What this study adds.

- Capmatinib inhibits P-gp and BCRP at a clinically relevant therapeutic dose.
- The results of this study will inform the safe use of P-gp and BCRP substrates when coadministration of capmatinib is required.

ABSTRACT

Aims

Capmatinib, an orally bioavailable, highly potent and selective MET inhibitor, was recently approved to treat adult patients with metastatic non-small cell lung cancer with *METex14* skipping mutations. The study investigated the effect of capmatinib on the pharmacokinetics of a single oral dose of digoxin and rosuvastatin, administered orally as a two-drug cocktail in patients with *MET* -dysregulated advanced solid tumors.

Methods

This was a multicenter, open-label, single-sequence study. An oral drug cocktail containing 0.25 mg digoxin and 10 mg rosuvastatin was administered to adult patients with *MET*- dysregulated advanced solid tumors

on Day 1, and then on Day 22 with capmatinib. Between Days 11 and 32, capmatinib 400 mg was administered twice daily to ensure the attainment of steady state for drug-drug interaction (DDI) assessment. Pharmacokinetics of cocktail drugs and safety of capmatinib were evaluated.

Results

Thirty-two patients (median age: 61.5 years) were enrolled. Co-administration of capmatinib increased digoxin C_{max}, and AUC_{inf} by 74%, and 47%, respectively. Co-administration of capmatinib increased rosuvastatin C_{max}, and AUC_{inf} by 204%, and 108%, respectively. Most frequent adverse events (AEs; [?]25% for all grades) were nausea (56.3%), asthenia (43.8%), constipation and vomiting (40.6%, each), peripheral edema (28.1%) and pyrexia (25%). Most frequent Grade 3/4 AEs ([?]5%) were anemia and pulmonary embolism (9.4%, each), asthenia, dyspnea, nausea and vomiting (6.3%, each).

Conclusion

This study demonstrated that capmatinib is an inhibitor of P-gp as well as BCRP transporters, with clinically relevant DDI potential. Capmatinib was well-tolerated and no unexpected safety concerns were observed.

Keywords: Capmatinib, INC280, Rosuvastatin, Digoxin, Pharmacokinetics, MET

INTRODUCTION

Dysregulation of MET-pathway has been implicated in the pathogenesis of several human cancers including papillary renal cell carcinoma and thyroid, prostate, lung, breast, ovarian, and gastrointestinal malignancies [1-4] and in the development of resistance to chemotherapy and radiotherapy, leading to poor clinical outcomes [5-8]. The dysregulation of MET pathway may occur by different mechanisms including gene mutation, amplification, overexpression, and constitutive activation [9].

Capmatinib, an orally bioavailable, highly potent and selective MET inhibitor, was recently approved to treat adult patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (*METex14*) skipping mutations [10]. Capmatinib has also shown*in vitro* and *in vivo* activities across a range of tumor models with *MET* amplification and/or overexpression [11, 12]. Phase I and Phase II studies have shown a manageable safety and robust efficacy profile of capmatinib, both as monotherapy and in combination with other anticancer therapies, in patients with solid tumors [13-20].

The therapeutic dose of capmatinib is 400 mg twice daily. Following oral administration, capmatinib absorbed rapidly with time to maximum plasma concentration (T_{max}) of 1-2 hours. The steady state was expected to be reach by Day 3 of consecutive twice daily dosing. Capmatinib is mainly metabolized by CYP3A4 and aldehyde oxidase.*In vitro,* capmatinib inhibits p-glycoprotein (P-gp) and breast cancer resistant protein (BCRP) with a IC50 of 12.0 µM and 16.4 µM, respectively. At the recommended phase II dose, capmatinib was predicted to inhibit P-gp and BCRP in vivo based on the ratio of capmatinib concentration in plasma and/or gut to Ki ([I]/Ki [R]) for P-gp and BCRP, and lead to increase in concentration of P-gp or BCRP substrates.

In clinical trials, patient populations are selected with limited or no comorbidities and concurrent medications are not permitted, follow-up period is much narrower, and the toxicities are detected earlier, so patient populations enrolled may not accurately represent the general oncology population [21]. Multiple drug therapy is also common in patients with cancer to treat their cancer or to manage the adverse effects and

comorbidities. Some of these drugs are substrates of P-gp and/or BCRP [22]. Understanding the *in vivo* drug-drug interaction (DDI) potential of capmatinib and substrates of P-gp or BCRP will inform the safe use of capmatinib in treating cancer patients. The purpose of this study was to investigate the effect of multiple doses of capmatinib on the pharmacokinetics of a single oral dose of digoxin and rosuvastatin, administered orally as a two-drug cocktail in patients with *MET* -dysregulated advanced solid tumors.

METHODS

Study design

This multicenter, open-label, single-sequence study (NCT02626234) consisted of a molecular pre-screening period, a screening/baseline period, a DDI phase and post-DDI phase or treatment phase (**Fig. 1**).

Baseline evaluations were performed within 28 days prior to the first dose of the probe drugs (digoxin and rosuvastatin). In the DDI phase (Day 1 to Day 32), a single oral dose of two probe drugs was administered as a two-drug cocktail on Day 1. No treatment was administered from Day 2 to Day 10 (washout phase). From Day 11 to Day 21, capmatinib tablets (400 mg twice daily, given 12 hours apart) were administered on a continuous dosing schedule. On Day 22, the two probe drugs and capmatinib were administered together. Administration of capmatinib 400 mg twice daily was continued until the end of the DDI phase (from Day 23 to Day 32). From Day 22 onwards, pharmacokinetic samples were collected relative to the end of the probe drugs ingestion for measurement of digoxin, rosuvastatin and capmatinib plasma concentrations at various time points during the DDI phase. All patients who entered the DDI phase were required to have an end of phase visit after the DDI phase. After completion of the DDI phase, patients were allowed to continue treatment with capmatinib 400 mg twice daily, administered orally on continuous 21-day cycles. All patients who entered the post-DDI phase were required to have an end of treatment visit. When the patient discontinued from the post-DDI phase, the end of treatment visit was performed as soon as possible and within 7 days of the last dose.

Patients were contacted for a safety follow-up 30 days after the last dose of study treatment, regardless of the reason for discontinuation from study treatment. Any adverse events (AEs) or serious adverse events (SAEs) occurred after discontinuation of study treatment and follow-up on resolution of ongoing AEs were recorded. If the study drug was discontinued for reasons other than documented disease progression or withdrawal of consent, patients were followed-up with tumor assessments until progression determined by investigator's assessments, start of new anticancer therapy or death.

Patients

Adult patients ([?]18 years of age) with *MET* -dysregulated advanced solid tumors refractory to currently available therapies or for which no effective therapy was available were enrolled in this study.*MET* -dysregulation was defined as either *MET* amplification (determined by fluorescence in situ hybridization or quantitative polymerase chain reaction with a gene copy number [?]4) or *MET*overexpression (determined by *MET* immunohistochemistry intensity score +3 in [?]50% of tumor cells) or *MET* mutation (leading to exon 14 deletion). Other inclusion criteria included availability of at least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, an Eastern Cooperative Oncology Group performance status (ECOG PS) [?]1, and an adequate organ function. Prior to receiving capmatinib, patients must have recovered from any previous anticancer treatment-related toxicities to Grade [?]1 of the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. However, patients with any grade of alopecia were eligible.

Patients were excluded if they had known hypersensitivity to digoxin or rosuvastatin or any of the excipients of capmatinib, digoxin or rosuvastatin or have inadequate organ function. Patient receiving following treatments were excluded: digoxin or rosuvastatin within 21 days prior to the beginning of the DDI phase (Day 1) and for the duration of the DDI phase; strong or moderate *in vivo* inhibitors and inducers of CYP3A4 that

cannot be discontinued at least 1 week prior to the start of treatment with capmatinib and for the duration of the study; *in vivo* inhibitors or inducers of P-gp or BCRP within 30 days prior to starting study treatment, or during the DDI phase; medicines with a known risk of prolonging the QT interval; unstable or increasing doses of corticosteroids; proton pump inhibitors within 7 days prior to starting study treatment or during the DDI phase; thoracic radiotherapy to lung fields [?]4 weeks prior to starting the capmatinib or patients who did not recover from radiotherapy-related toxicities; major surgery (except video-assisted thoracic surgery and mediastinoscopy) within 4 weeks prior (2 weeks for resection of brain metastases) to starting capmatinib or patients who did not recover from side-effects of such procedure; homeopathic or naturopathic medicines (except vitamin supplements) within 5 days prior to the days of blood sample collection for pharmacokinetic assessment in the DDI phase (i.e., Day 5 to Day 10 and Day 17 to Day 32 of the DDI phase).

This clinical study was designed and implemented in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonization, with applicable local regulations. The study protocol and all amendments were reviewed by the independent ethics committee or institutional review board for each center. All patients provided written informed consent before screening.

Blood sample collection and bioanalysis

Blood samples (3, 7 or 10 mL per sample) for measurement of plasma concentration of digoxin and rosuvastatin were collected before the administration of capmatinib (Day 1 to Day 11 of DDI phase) and after the administration (Day 22 to Day 32 of DDI phase), at various time points (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216 and 240 hours post-dose). Blood samples for measurement of pharmacokinetics of capmatinib were collected during the DDI phase (pre-dose on Day 22) and post-DDI phase (pre-dose and 2 hours post-dose on Cycle 2 Day 1).

Plasma concentrations of digoxin, rosuvastatin and capmatinib were determined using a validated liquid chromatography-tandem mass spectrometry assay with a lower limit of quantification of approximately 0.05, 0.05, and 1.00 ng/mL for digoxin, rosuvastatin and capmatinib, respectively.

Efficacy evaluations

Antitumor activity of capmatinib was evaluated by Investigator's assessment per RECIST 1.1 with computed tomography scans conducted every 6 weeks.

Safety evaluations

Safety assessments included incidence of AEs and SAEs. Data on AEs/SAEs were collected at every visit and coded using the latest version of Medical Dictionary for Regulatory Activities version 20.1 and were graded using CTCAE version 4.03. All patients were followed-up for AEs/SAEs for at least 30 days following the last dose of study treatment.

Pharmacokinetics and statistical analysis

A sample size of 18 evaluable patients was selected to provide reasonable precision for the estimation of the effect of capmatinib on pharmacokinetics of digoxin and rosuvastatin, assuming the intra-patient coefficient of variation (CV) of digoxin (44.7%) and rosuvastatin (31.5%). Using these intra-patient CV% estimates and a sample size of 18, the half-width of the 90% confidence intervals (CIs) for treatment difference comparison (capmatinib + digoxin vs. digoxin alone; capmatinib + rosuvastatin vs. rosuvastatin alone) on the log scale was 0.247 for digoxin and 0.178 for rosuvastatin. These calculations were based on t-distribution with one-sided α-level of 0.05 and N-1 degrees of freedom. Due to the strict evaluability criteria and the requirement to conduct the DDI test at steady state, the total number of patients enrolled was expected to be approximately 32.

The pharmacokinetic analysis was based on patients in the pharmacokinetic analysis set. Three separate sets were considered; one for each of the probe drugs (digoxin and rosuvastatin) and one for capmatinib. For each of the probe drugs, all patients who provided an evaluable pharmacokinetic profile for all periods (first period

after the cocktail administration and second period after administration of cocktail + capmatinib) were included for analysis. A profile was considered evaluable if patient received the planned dose of capmatinib on Day 22 and at least 3 consecutive days prior to co-administration with probe drugs; received planned dose of probe drugs, did not vomit within 4 hours after receiving capmatinib or probe drugs and provided at least one primary pharmacokinetic parameter (AUC_{inf}, AUC_{last}, or C_{max}) for probe drugs. Pharmacokinetic analysis set for capmatinib included all patients who provided at least one evaluable concentration for capmatinib; a concentration was evaluable if patients received the same dose of capmatinib at least 3 consecutive days prior to sampling, did not vomit within 4 hours after receiving capmatinib, and had pre-dose samples collected before the next dose administration and 9 to 15 hours after the last dose administration.

Pharmacokinetic parameters were estimated by a non-compartmental method using Phoenix WinNonlin 6.4 (Pharsight, Mountain View, CA). The log-transformed pharmacokinetic parameters (AUC_{last}, AUC_{inf} and C_{max}) were analyzed using a linear mixed model to assess the effect of multiple doses of capmatinib on the pharmacokinetics of a single oral dose of each of the probe drugs separately. The model included treatment (probe + capmatinib and probe alone) as a fixed effect and patient as a random effect. Point estimates of treatment differences and the corresponding 90% CIs were calculated and anti-logged to obtain the point estimates and 90% CI for the geometric means ratio of the probe + capmatinib versus probe alone on the original scale.

RESULTS

Patient disposition

A total of 32 patients were enrolled in the study. Of these, 26 patients (81.3%) completed the DDI phase. The reasons for DDI phase discontinuation were AEs (two patients [6.3%]), physician's decision (two patients [6.3%]), disease progression (one patient [3.1%]) and death (one patient [3.1%], **Table 1**). Of the two patients who discontinued the DDI phase due to AEs, one had experienced Grade 3 blood bilirubin and Grade 4 encephalopathy (both non-treatment related), and another patient had experienced Grade 3 abdominal pain and Grade 3 vomiting, both were treatment-related.

A total of 27 patients (84.4%) entered the treatment (post-DDI) phase, all of whom discontinued the study; the primary reason for discontinuation was PD (20 patients [62.5%]). Three patients (9.4%) discontinued from the treatment phase (post-DDI) due to physician decision and one patient each (3.1%, each) discontinued due to AE (Grade 3 pulmonary embolism; non-treatment related) and being lost to follow-up. Two patients (6.3%) died during the post-DDI phase; one due to PD and another due to Grade 3 respiratory tract infection (non-treatment related). One patient (3.1%) entered the post-treatment follow-up phase. However, this patient was discontinued due to protocol deviation. The patient received rosuvastatin during the DDI phase except on Day 1 and Day 22. All 32 patients enrolled in the study were included in the full analysis set and safety set. Of these, 25 (78.1%), 24 (75.0%), and 17 (53.1%) patients were included in pharmacokinetic analysis set for digoxin, rosuvastatin, and capmatinib, respectively.

Patient demographics and disease characteristics

The median age of the patients who participated in the study was 61.5 years (range: 38-81 years). Patients were equally divided by sex, and almost all were Caucasian (30 patients [93.8%]). Most patients (24 [75%]) had an ECOG PS of 1. The median body mass index was 23.95 kg/m^2.

The most frequent primary site of cancer was colon (10 patients [31.3%]), followed by lung (eight patients [25%]), esophagus, oral cavity, pancreas and rectum (two patients [6.3%], each); other cancers (one patient [3.1%], each; **Table 2**). Predominant tumor histology was adenocarcinoma (22 patients [68.8%]). A majority of the patients had metastatic (stage IV) disease at initial diagnosis (18 patients [56.3%]) and at study entry (27 patients [84.4%]). Key sites of metastatic disease included lung (21 patients [65.6%]), liver (19 patients [59.4%]), bone, lymph nodes, and peritoneum (six patients [18.8%], each). All patients had *MET*

dysregulation at study entry, with some having had more than one *MET* alteration. *MET* mutation was reported in four patients (9.4%; all had *METex14*), *MET* overexpression in 24 (75%) and *MET* amplification in 14 (43.8%) patients.

The median time from initial diagnosis to first study treatment was 25.23 months (range: 8.6 to 124.2) and the median time from most recent relapse/progression to the first study treatment was 1.99 months (range: 0.7 to 7.1). All patients enrolled in the study received at least one prior antineoplastic therapy. Overall, 31 patients (96.9%) received prior antineoplastic chemotherapy. Eleven patients (34.4%) received two prior lines of chemotherapy, three patients (9.4%) received three prior lines of chemotherapy and 15 patients (46.9%) received four or more lines of prior chemotherapy. 68.8% of patients received chemotherapy in a therapeutic setting as prior antineoplastic therapy. The best response to last therapy in patients receiving prior antineoplastic therapy excluding surgery was predominantly PD, which was noted in 21 patients (65.6%). A total of 84.4% of patients received concomitant medications. Pharmacokinetics of digoxin

The geometric and arithmetic mean concentration-time profiles of digoxin are shown in **Fig 2** . Digoxin concentration was higher throughout 72-hour sampling with coadministration of capmatinib versus digoxin alone. The pharmacokinetic parameters are summarized in **Table 3** . Coadministration of capmatinib increased digoxin AUC_{inf}, AUC_{last} and $C_{max}$by 47%, 63% and 74%, respectively, compared to digoxin alone. The geometric mean ratios (90% CI) were 1.47 (1.28, 1.68) for AUC_{inf}, 1.63 (1.42, 1.89) for $AUC_{last}$and 1.74 (1.43, 2.13) for C_{max} (**Table 4**). Consistently, the apparent clearance (CL/F) was lower with coadministration of capmatinib (7.33 L/h) compared to digoxin alone (9.89 L/h). Slightly longer half-life (T1/2/) was observed with coadministration of capmatinib (61.4 h) compared to digoxin alone (47 h) as the elimination slope was parallel in general. $T_{max}$was not affected by capmatinib.

Pharmacokinetics of rosuvastatin

The geometric and arithmetic mean concentration-time profiles of rosuvastatin are shown in **Fig 2** . The concentration of rosuvastatin was higher throughout the 72 hours timeframe following capmatinib coadministration with the more significant difference observed in the absorption phase (first 12 hours). The elimination slope was very similar with or without coadministration of capmatinib. The pharmacokinetic parameters for rosuvastatin are summarized in**Table 3** . Coadministration of capmatinib increased the geometric means of AUC_{inf}, AUC_{last} and C_{max} by 108%, 103%, and 204%, respectively, compared to rosuvastatin alone. The geometric mean ratios (90% CI) were 2.08 (1.56, 2.76) for AUC_{inf}, 2.03 (1.61, 2.56) for AUC_{last} and 3.04 (2.36, 3.92) for C_{max}(**Table 4**). Consistently, the apparent clearance (CL/F) was significantly lower (62.8 L/hr) with coadministration of capmatinib compared to rosuvastatin alone (128 L/hr). However, the elimination half-life was not affected by capmatinib.

Pharmacokinetics of capmatinib

The geometric mean pre-dose concentration of capmatinib on Day 22 (DDI phase) was 407 ng/mL. On Cycle 2 Day 1 (post-DDI phase), the geometric mean pre-dose and 2 hour post-dose concentrations of capmatinib were 529 and 3960 ng/mL, confirming that steady state has been obtained.

Efficacy assessments

No patient achieved a complete response (CR) or partial response (PR). Eight (25%) patients had stable disease (SD) as best overall response (BOR), while 17 (53.1%) had PD. Response was unknown for seven patients (21.9%). The disease control rate (CR+PR+SD) was 25% (**Table 5**).

Safety assessments

The median (range) percentage of the relative dose intensity was 100% (76.8-100.0), and the mean (±SD) percentage was 98.28% (±4.82). The median actual dose intensity was 800 mg/day (range: 614.3, 800). The median duration of exposure for capmatinib was 7.14 weeks (range: 1.4 to 42.0) for all patients. 43.8% patients received capmatinib for a duration of 6 to 12 weeks.

All 32 enrolled patients experienced at least one AE, regardless of study drug relationship; of these, 18 patients (56.3%) had Grade 3/4 AEs (**Table 6**). The most frequent AEs regardless of study drug relationship ([?]20% for all grades) were nausea (56.3%), asthenia (43.8%), constipation and vomiting (40.6%, each), peripheral edema (28.1%), pyrexia (25%), anemia, decreased appetite, and dyspepsia (21.9%, each). The most frequent Grade 3/4 AEs ([?]5%) regardless of study drug relationship were anemia and pulmonary embolism (9.4%, each), asthenia, dyspnea, nausea and vomiting (6.3%, each). No clinically relevant alterations were observed in the electrocardiograph. Treatment-related AEs were reported in 25 patients (78.1%); of these, eight (25.0%) had Grade 3/4 AEs. Most common treatment-related AEs ([?]10%, all grades) were nausea and vomiting (34.4%, each), asthenia (18.8%), dyspepsia (15.6%), and peripheral edema (12.5%). Most frequent treatment-related Grade 3/4 AE ([?]5%) was vomiting (6.3%). AEs leading to study drug discontinuation were reported in three patients (9.4%); all of the events were grade 3/4 in severity. Treatment-related AEs leading to study drug discontinuation were Grade 3 abdominal pain and Grade 3 vomiting. AEs requiring dose adjustment or study drug interruption were reported in 13 patients (40.6%). The most frequent AE that led to dose adjustment or dose interruption was nausea (6.3%; both Grade [?]2 in severity).

Seventeen patients (53.1%) experienced SAEs of any grade, regardless of study drug relationship; of these, 13 patients (40.6%) had Grade 3/4 SAEs. Treatment-related SAEs were reported in four patients (12.5%). Most frequently reported treatment-related SAE was vomiting occurring in three patients (9.4%). Other treatment-related SAEs were anemia, abdominal pain and malaise, reported in one patient each. In total, eight patients (25.0%) died during the study; of these, six (18.8%) were on-treatment deaths. Of the on-treatment deaths, two deaths (6.3%) were due to disease progression, three (9.4%) due to AEs with disease progression as contributing reason and one (3.1%) died due to AE (respiratory tract infection).

DISCUSSION

In vitro data suggested that capmatinib can inhibit transporters P-gp (Ki of 12.0 μM) and BCRP (Ki of 8.20 μM) (data on file). At the therapeutic dose of 400 mg twice daily, the estimated maximum luminal concentration in the gut was approximately 3880 μM (dose/250 mL), which was >300-fold of the Ki for P-gp and BCRP. Therefore, a clinical DDI study was considered necessary to confirm whether capmatinib is likely to inhibit intestinal P-gp and BCRP and potentially result in an increase in the absorption of P-gp and BCRP substrates. This study was thus conducted in patients with *MET* -dysregulated advanced solid tumors, and capmatinib was given as multiple doses until attaining steady state which allows for an assessment of the maximum inhibition effect of capmatinib on P-gp and BCRP in the relevant patient population.

The two selected probe drugs (digoxin and rosuvastatin) were administered simultaneously as a two-drug cocktail, as the cocktail approach offers advantages such as reduced study duration and increased efficiency [23] compared to the administration of individual probes in separate studies. Digoxin and rosuvastatin are established as sensitive probes to evaluate the potential impact of other drugs on P-gp and BCRP, and no interaction between these two probe drugs are expected [24].

Digoxin is rapidly absorbed following oral administration, with a peak serum concentrations occuring at 1 to 3 hours. Digoxin is mostly eliminated via urinary excretion as parent drug. The $T_{1/2}$ in healthy subjects with normal renal function is 1.5-2 days [25, 26]. As [Imax,u]/Ki for renal P-gp is 0.04 compared to the ratio of >300 for intestinal P-gp, capmatinib was not expected to inhibit renal clearance of digoxin. Thus, this study would reflect the inhibition of intestinal P-gp by capmatinib. Rosuvastatin is eliminated mainly through an efflux-mediated process in the gut and in bile with minimum metabolism. The $T_{1/2}$ is approximately 19

hours [27, 28]. Based on the half-lives, a total of 21-day washout period was implemented between the first and second dose of probe drugs to allow a complete elimination of probe drugs. A long pharmacokinetic sampling schedule up to 240 hours has ensured the capture of complete pharmacokinetic profiles for both probe drugs.

The study population consisted of 32 patients with MET-dysregulated advanced solid tumors, who had been treated with at least one prior line of treatment. The pharmacokinetics of digoxin and rosuvastatin, considered independently, were comparable to those reported in literature reports [25-30]. Co-administration of capmatinib and digoxin increased C_{max}, AUC_{last} and AUC_{inf} by 74%, 63%, and 47%, respectively and co-administration of capmatinib and rosuvastatin increased the C_{max}, AUC_{last} and $AUC_{inf}$by 204%, 103%, and 108%, respectively.

In vitro, capmatinib showed inhibition of hepatic uptake transporter organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 with Ki values of 5.1 and 5.2 μM, respectively (data on file). The DDI assessment resulted in R-values of 1.12 and 1.13, respectively, using calculated hepatic inlet concentration, which indicated a low risk of inhibition (R=1+ [(fu,p × Iin,max)/Ki]) [31]. In this study, the probe substrate rosuvastatin is a substrate for BCRP and OATP, so the result obtained reflected the worst-case scenario of the impact on rosuvastatin pharmacokinetics by capmatinib. However, based on R-value assessment for BCRP and OATP, the increase of rosuvastatin exposure should be mainly due to the inhibition on BCRP with little or no contribution from the inhibition of OATP. Consistent with this, the rosuvastatin clinical pharmacokinetics data indicated that the increase occurred mainly in the absorption phase, with no/little change on the $T_{1/2}$ of rosuvastatin.

In this population with *MET* -dysregulated advanced solid tumors, no patient achieved CR or PR. BOR of SD was observed in 25% of the patients. While the predictive role of specific MET alterations, primarily *METex14* skipping mutations, has recently become more established in some indications like NSCLC, the predictive role of others, like MET amplification and overexpression, remain exploratory particularly in indications other than NSCLC. Taken altogether with the limited sample size of this study, which was not primarily designed or powered to evaluate antitumor activity of capmatinib, no conclusions can be made on efficacy of capmatinib in patients with*MET* -dysregulated advanced solid tumors.

The overall safety results of capmatinib in this study were mostly in line with those seen with other capmatinib studies conducted in patients with advanced solid malignancies with no new or unexpected safety concerns observed [13-15, 17]. The most common treatment-related AEs were nausea and vomiting, asthenia, dyspepsia, and peripheral edema, while treatment-related SAEs were vomiting, anemia, abdominal pain and malaise. All these AEs were manageable by routine oncology patient monitoring and supportive care.

In summary, the clinical data from this study confirms that capmatinib is an inhibitor of P-gp and BCRP transporters, with clinically relevant DDI potential. In addition, capmatinib was well-tolerated by the study population with no major or new safety concerns.

ACKNOWLEDGMENTS

The authors thank Manojkumar Patel (Novartis Healthcare PVT Ltd) for providing medical writing support, which was funded by Novartis Pharmaceutical Corporation in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). We thank Dr. Felix Huth, Novartis Institute of Biomedical Research, for providing the in vitro data.

CONFLICT OF INTEREST

Enrique Grande reports research grants from Roche, Pfizer, BMS, IPSEN, EUSA Pharma, Lexicon, MTEM/Threshold and AstraZeneca; advisory role for Roche, Pfizer, BMS, IPSEN, EUSA Pharma, MSD, Sanofi and Adacap; travel support from Roche, Pfizer, BMS, and IPSEN; and lecture honoraria from Pierre Fabre. Giuseppe Curigliano serves on the advisory board of the Roche, Novartis, Pfizer, Lilly, Daichii Sankyo, and AstraZeneca; serves on scientific committee of Ellipsis and is a member of Steering Committee of the BMS. Monica Giovannini, Eddie Marriere, Xinhui Chen, Philippe Pultar, Michelle Quinlan, Xiaoming Cui

are employees of Novartis. Xinhui Chen, Philippe Pultar, Michelle Quinlan and Xiaoming Cui own Novartis stock.

AUTHORS CONTRIBUTION

Enrique Grande, Philippe Pultar, Xinhui Chen and Giuseppe Curigliano contributed to patient accrual, data analysis, data interpretation, writing and critical revision of the manuscript. Xiaoming Cui, Monica Giovannini and Eddie Marriere contributed to designing the study, patient accrual, data analysis, data interpretation, writing and critical revision of the manuscript. Michelle Quinlan contributed to writing and critical revision of the manuscript. All authors have read and approved the final version of this manuscript.

FUNDING

This study was funded by Novartis Pharmaceutical Corporation.

DATA AVAILABILITY STATEMENT

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

REFERENCES

1. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B. Germline And Somatic Mutations In The Tyrosine Kinase Domain Of The MET Proto-Oncogene In Papillary Renal Carcinomas. Nature Genetics 1997; 16: 68-73.

2. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina G, Comoglio PM. Somatic Mutations Of The MET Oncogene Are Selected During Metastatic Spread Of Human HNSC Carcinomas. Oncogene 2000; 19: 1547-55.

3. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB. A Selective Small Molecule Inhibitor Of C-Met Kinase Inhibits C-Met-Dependent Phenotypes In Vitro And Exhibits Cytoreductive Antitumor Activity In Vivo. Cancer Research 2003; 63: 7345-55.

4. Davis IJ, Mcfadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE. Identification Of The Receptor Tyrosine Kinase C-Met And Its Ligand, Hepatocyte Growth Factor, As Therapeutic Targets In Clear Cell Sarcoma. Cancer Research 2010; 70: 639-45.

5. Akervall J, Guo X, Qian CN, Schoumans J, Leeser B, Kort E, Cole A, Resau J, Bradford C, Carey T, Wennerberg J, Anderson H, Tennvall J, Teh BT. Genetic And Expression Profiles Of Squamous Cell Carcinoma Of The Head And Neck Correlate With Cisplatin Sensitivity And Resistance In Cell Lines And Patients. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2004; 10: 8204-13.

6. Lal B, Xia S, Abounader R, Laterra J. Targeting The C-Met Pathway Potentiates Glioblastoma Responses To Gamma-Radiation. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2005; 11: 4479-86.

7. Liu X, Yao W, Newton RC, Scherle PA. Targeting The C-MET Signaling Pathway For Cancer Therapy. Expert Opinion On Investigational Drugs 2008; 17: 997-1011.

8. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro A, Varella-Garcia M. Increased MET Gene Copy Number Negatively Affects Survival Of Surgically Resected Non-Small-Cell Lung Cancer Patients. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2009; 27: 1667-74.

9. Sierra JR, Tsao MS. C-MET As A Potential Therapeutic Target And Biomarker In Cancer. Therapeutic Advances In Medical Oncology 2011; 3: S21-35.

10. US Food And Drug Administration. Capmatinib Oral Tablet Prescribing Information. Available At: Https://Www.Accessdata.Fda.Gov/Drugsatfda_Docs/Label/2020/213591s000lbl.Pdf. Accessed On 18 May 2020.

11. Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, Fridman JS, Behshad E, Wynn R, Li Y, Boer J, Diamond S, He C, Xu M, Zhuo J, Yao W, Newton RC, Scherle PA. A Novel Kinase Inhibitor, INCB28060, Blocks C-MET-Dependent Signaling, Neoplastic Activities, And Cross-Talk With EGFR And HER-3. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2011; 17: 7127-38.

12. Baltschukat S, Engstler BS, Huang A, Hao HX, Tam A, Wang HQ, Liang J, Dimare MT, Bhang HC, Wang Y, Furet P, Sellers WR, Hofmann F, Schoepfer J, Tiedt R. Capmatinib (INC280) Is Active Against Models Of Non-Small Cell Lung Cancer And Other Cancer Types With Defined Mechanisms Of MET Activation. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019; 25: 3164-75.

13. Schuler MH, Berardi R, Lim W-T, Geel RV, Jonge MJD, Bauer TM, Azaro A, Gottfried M, Han J-Y, Lee DH, Wollner M, Hong DS, Vogel A, Delmonte A, Krohn A, Zhang Y, Squires M, Giovannini M, Akimov M, Bang Y-J. Phase (Ph) I Study Of The Safety And Efficacy Of The Cmet Inhibitor Capmatinib (INC280) In Patients (Pts) With Advanced Cmet+ Non-Small Cell Lung Cancer (NSCLC). Journal Of Clinical Oncology 2016; 34: 9067-67.

14. Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, Akimov M, Tan DSW. Phase Ib/II Study Of Capmatinib (INC280) Plus Gefitinib After Failure Of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy In Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018; 36: 3101-09.

15. Wolf J, Han J, Nishio M, Souquet P, Paz-Ares L, De Marinis F, Seto T, De Jonge M, Kim TM, Vansteenkiste J, Tan Dsw, Garon EB, Groen H, Hochmair MJ, Felip E, Reguart N, Thomas M, Overbeck T, Ohashi K, Giovannini M, Yura R, Joshi A, Akimov M, Heist R. PS04.06 GEOMETRY Mono-1: Phase II, Multicenter Study Of MET Inhibitor Capmatinib (INC280) In EGFR Wt, MET-Dysregulated Advanced NSCLC. Journal Of Thoracic Oncology 2017; 12: S1578-S79.

16. Bang Y-J, Su W-C, Nam D-H, Lim W-T, Bauer TM, Brana I, Poon RT-P, Hong DS, Lin C-C, Peng B, Zhang Y, Zhao S, Kumar A, Akimov M, Ma B. Phase I Study Of The Safety And Efficacy Of INC280 In Patients With Advanced MET-Dependent Solid Tumors. Journal Of Clinical Oncology 2014; 32: 2520-20.

17. Esaki T, Hirai F, Makiyama A, Seto T, Bando H, Naito Y, Yoh K, Ishihara K, Kakizume T, Natsume K, Myers A, Doi T. Phase I Dose-Escalation Study Of Capmatinib (INC280) In Japanese Patients With Advanced Solid Tumors. Cancer Science 2019; 110: 1340-51.

18. Bang YJ, Su WC, Schuler M, Nam DH, Lim WT, Bauer TM, Azaro A, Poon RTP, Hong D, Lin CC, Akimov M, Ghebremariam S, Zhao S, Giovannini M, Ma B. Phase 1 Study Of Capmatinib In MET-Positive Solid Tumor Patients: Dose Escalation And Expansion Of Selected Cohorts. Cancer Science 2020; 111: 536-47.

19. Qin S, Chan SL, Sukeepaisarnjaroen W, Han G, Choo SP, Sriuranpong V, Pan H, Yau T, Guo Y, Chen M, Ren Z, Xu J, Yen CJ, Lin ZZ, Manenti L, Gu Y, Sun Y, Tiedt R, Hao L, Song W, Tanwandee T. A Phase II

Study Of The Efficacy And Safety Of The MET Inhibitor Capmatinib (INC280) In Patients With Advanced Hepatocellular Carcinoma. Therapeutic Advances In Medical Oncology 2019; 11: 1758835919889001.

20. Reungwetwattana T, Liang Y, Zhu V, Ou SI. The Race To Target MET Exon 14 Skipping Alterations In Non-Small Cell Lung Cancer: The Why, The How, The Who, The Unknown, And The Inevitable. Lung Cancer (Amsterdam, Netherlands) 2017; 103: 27-37.

21. Feliu J, Heredia-Soto V, Girones R, Jimenez-Munarriz B, Saldana J, Guillen-Ponce C, Molina-Garrido MJ. Can We Avoid The Toxicity Of Chemotherapy In Elderly Cancer Patients? Critical Reviews In Oncology/Hematology 2018; 131: 16-23.

22. Van Leeuwen RW, Van Gelder T, Mathijssen RH, Jansman FG. Drug-Drug Interactions With Tyrosine-Kinase Inhibitors: A Clinical Perspective. The Lancet Oncology 2014; 15: E315-26.

23. Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, Boulenc X. Pharmacokinetic Assessment Of A Five-Probe Cocktail For Cyps 1A2, 2C9, 2C19, 2D6 And 3A. British Journal Of Clinical Pharmacology 2009; 68: 928-35.

24. Otani N, Wakuda H, Imai H, Kuranari M, Ishii Y, Ito Y, Okubo A, Ogawa O, Takeda K, Ohyama T, Hasunuma T, Uemura N. No Effect Of Digoxin On Rosuvastatin Pharmacokinetics In Healthy Subjects: Utility Of Oita Combination For Clinical Drug-Drug Interaction Study. Clinical And Translational Science 2019.

25. Einfeld SL, Piccinin AM, Mackinnon A, Hofer SM, Taffe J, Gray KM, Bontempo DE, Hoffman LR, Parmenter T, Tonge BJ. Psychopathology In Young People With Intellectual Disability. Jama 2006; 296: 1981-9.

26. Tye C, Mcewen FS, Liang H, Underwood L, Woodhouse E, Barker ED, Sheerin F, Yates JRW, Bolton PF. Long-Term Cognitive Outcomes In Tuberous Sclerosis Complex. Developmental Medicine And Child Neurology 2020; 62: 322-29.

27. Krueger DA, Northrup H. Tuberous Sclerosis Complex Surveillance And Management: Recommendations Of The 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology 2013; 49: 255-65.

28. Nabbout R, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, Dahlin M, L DA, d'Augeres GB, De Vries PJ, Ferreira JC, Feucht M, Fladrowski C, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Marques R, O'Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Jansen A, Kingswood JC. Epilepsy In Tuberous Sclerosis Complex: Findings From The TOSCA Study. Epilepsia Open 2019; 4: 73-84.

29. Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No Effect Of Rosuvastatin On The Pharmacokinetics Of Digoxin In Healthy Volunteers. Journal Of Clinical Pharmacology 2002; 42: 1352-7.

30. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D. Rosuvastatin Pharmacokinetics And Pharmacogenetics In White And Asian Subjects Residing In The Same Environment. Clinical Pharmacology And Therapeutics 2005; 78: 330-41.

31. US Food And Drug Administration. In Vitro Metabolism- And Transporter-Mediated Drug-Drug Interaction Studies: Guidance For Industry. [Draft Guidance 2017]. Available At: Https://Www.Fda.Gov/Regulatory-Information/Search-Fda-Guidance-Documents/Vitro-Metabolism-And-Transporter-Mediated-Drug-Drug-Interaction-Studies-Guidance-Industry. Accessed On 18 May 2020.

TABLES

Table 1 Patient disposition

Disposition/Reason	All patients N=32 n (%)
Pharmacokinetic phase (DDI phase)	
Completed	26 (81.3)
Entered post-DDI (treatment) phase	26 (81.3)
Discontinued from PK phase	6 (18.8)
Entered post-DDI (treatment) phase	1 (3.1)
Entered post-treatment follow-up phase	1 (3.1)
Primary reason for discontinuation from PK phase	
Adverse event	2 (6.3)
Physician decision	2 (6.3)
Progressive disease	1 (3.1)
Death	1 (3.1)
Post-DDI (treatment) phase	
Discontinued from post-DDI (treatment) phase	27 (84.4)
Primary reason for discontinuation from treatment phase	
Progressive disease	20 (62.5)
Physician decision	3 (9.4)
Death	2 (6.3)
Adverse event	1 (3.1)
Lost to follow-up	1 (3.1)
Post-treatment follow-up	
Discontinued from post-treatment follow-up	1 (3.1)
Primary reason for discontinuation from post-treatment follow-up	
Protocol deviation	1 (3.1)

Abbreviations: DDI, drug-drug interaction; PK, pharmacokinetic

Table 2 Patient demographics and disease characteristics at baseline

Characteristic	All patients N=32 n (%)
Median age (range), years	61.5 (38-81)
Sex, n (%)	
Female	15 (46.9)
Male	17 (53.1)
Race, n (%)	
White	30 (93.8)
Unknown	2 (6.3)
ECOG performance status, n (%)	
0	8 (25.0)
1	24 (75.0)
Primary site of cancer, n (%)	

Characteristic	**All patients N=32 n (%)**
Colon	10 (31.3)
Lung	8 (25.0)
Esophagus	2 (6.3)
Oral cavity	2 (6.3)
Pancreas	2 (6.3)
Rectum	2 (6.3)
Bladder	1 (3.1)
Duodenum	1 (3.1)
Kidney	1 (3.1)
Skin melanoma	1 (3.1)
Small intestine	1 (3.1)
Uterus	1 (3.1)
Stage at study entry, n (%)	
III	1 (3.1)
IIIB	2 (6.3)
IV	27 (84.4)
IVB	2 (6.3)
Type of lesion per investigator assessment at baseline, n (%)	
Both target and non-target	22 (68.8)
Target only	10 (31.3)
Number of metastatic sites of cancer, median (range)	3 (1-7)
MET **dysregulation**	
MET overexpression	24 (75)
MET amplification	14 (43.8)
MET mutation	3 (9.4)
Prior anti-cancer medications, n (%)	
Any	32 (100)
Chemotherapy	31 (96.9)
Surgery	17 (53.1)
Radiotherapy	14 (43.8)
Number of prior chemotherapy regimens, n (%)	
1	3 (9.4)
2	11 (34.4)
3	3 (9.4)
[?]4	15 (46.9)
Type of last therapy, n (%)	
Chemotherapy	19 (59.4)
Targeted therapy	7 (21.9)
Radiotherapy	3 (9.4)
Surgery	5 (15.6)
Other	6 (18.8)
Best response to last therapy[a], n (%)	
Stable disease	3 (9.4)
Progressive disease	21 (65.6)
Not applicable	14 (43.8)
Unknown	2 (6.3)

[a] Best response at last therapy was set to 'Not applicable' if the type of last therapy was surgery.

Abbreviation: ECOG, Eastern Cooperative Oncology Group

Table 3: Summary statistics of the pharmacokinetic parameters by treatment

Pharmacokinetic Parameters	Digoxin alone N=25	Digoxin alone N=25	Capmatinib + digoxin N=25	Capmatinib + digoxin N=25	Rosuvastatin alone N=24	Rosuvastatin alone N=24	Capmatinib + rosuvastatin N=24	Capma + rosuvastatin N=24
	n	Geo-mean (Geo-CV%)	n	Geo-mean (Geo-CV%)	n	Geo-mean (Geo-CV%)	n	Geo-mean (Geo-CV%)
AUC_{inf}, ng h/mL	9	25.3 (36.3)	12	34.1 (37.9)	21	78.2 (73.4)	22	159 (99.8)
AUC_{last}, ng h/mL	25	14.6 (58.0)	25	23.8 (50.5)	24	71.0 (71.3)	24	144 (102.6)
C_{max}, ng/mL	25	1.12 (57.9)	25	1.95 (56.8)	24	7.72 (73.4)	24	23.5 (85.5)
T_{max}, h[a]	25	1.07 (0.500, 6.00)	25	1.00 (0.417, 4.08)	24	2.04 (0.500, 6.00])	24	1.55 (0. 9.93)
$T_{1/2}$, h	9	47 (29.8)	12	61.4 (25.7)	21	22 (73.8)	22	21.4 (56.6)
CL/F, L/h	9	9.89 (36.3)	12	7.33 (37.9)	21	128 (73.4)	22	62.8 (99.8)
V_Z/F, L	9	671 (16.5)	12	649 (22.3)	21	4060 (80.2)	22	1940 (105.1)

[a]Median (min, max) is reported for T_{max}.

n=number of patients with corresponding evaluable pharmacokinetic parameters.

Abbreviations: AUC_{inf}, area under the concentration-time curve from time zero to infinity; AUC_{last}, area under the concentration-time curve from time zero to the last quantifiable concentration; CL/F, apparent total body clearance from plasma; C_{max}, maximum concentration; Geo-CV, geometric coefficient of variation; Geo-mean, geometric mean; $T_{1/2}$, elimination half-life determined as $0.693/\lambda z$; T_{max}, time to reach maximum plasma concentration; λz, terminal elimination rate constant; Vz/F, apparent volume of distribution during the terminal elimination phase.

Table 4: Statistical comparison of primary pharmacokinetic parameters between probe drug (digoxin or rosuvastatin) and capmatinib with probe drug.

PK parameter by probe drug	n	Adjusted geo-mean	Treatment comparison
			Geo-mean ratio (90% CI)
Digoxin			
AUC_{inf} (ng × h/mL)			
Probe drug alone	9	22.4	1.47 (1.28- 1.68)
Probe drug + capmatinib	12	32.9	

PK parameter by probe drug	n	Adjusted geo-mean	Treatment comparison
AUC_{last} (ng × h/mL)			
Probe drug alone	25	14.6	1.63 (1.42-1.89)
Probe drug + capmatinib	25	23.8	
C_{max} (ng/mL)			
Probe drug alone	25	1.12	1.74 (1.43-2.13)
Probe drug + capmatinib	25	1.95	
Rosuvastatin			
AUC_{inf} (ng × h/mL)			
Probe drug alone	21	75.2	2.08 (1.56-2.76)
Probe drug + capmatinib	22	156	
AUC_{last} (ng × h/mL)			
Probe drug alone	24	71	2.03 (1.61-2.56)
Probe drug + capmatinib	24	144	
C_{max} (ng/mL)			
Probe drug alone	24	7.72	3.04 (2.36-3.92)
Probe drug + capmatinib	24	23.5	

n=number of patients with corresponding evaluable pharmacokinetic parameters.

Model is a linear mixed effects model of the log-transformed PK parameters. Included in the model were treatment as a fixed factor and patient as a random factor. The results were back transformed to get adjusted geometric mean, geometric mean ratio, and 90% CI.

Abbreviations: AUC_{inf}, area under the concentration-time curve from time zero to infinity; AUC_{last}, area under the concentration-time curve from time zero to the last quantifiable concentration; CI, confidence interval; C_{max}, maximum concentration; Geo-mean, geometric mean; PK, pharmacokinetic.

Table 5. Best overall response per investigator assessment (per RECIST 1.1)

Best overall response	All patients N=32
Stable disease (SD), n (%)	8 (25.0)
Progressive disease (PD), n (%)	17 (53.1)
Unknown, n (%)	7 (21.9)
Disease control rate (DCR: CR + PR + SD + non-CR/non-PD), n (%) [95% CI]	8 (25.0) [11.5-43.4]

Abbreviations: CI, confidence interval; CR, complete response; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors.

Table 6. All-grade adverse events (in >5% of patients) and Grade 3/4 adverse events, regardless of study drug relationship

Preferred term	All patients N=33	All patients N=33
	All grades n (%)	**Grade 3/4 n (%)**
Total	32 (100)	18 (56.3)
Nausea	18 (56.3)	2 (6.3)
Asthenia	14 (43.8)	2 (6.3)
Constipation	13 (40.6)	0
Vomiting	13 (40.6)	2 (6.3)

Preferred term	All patients N=33	All patients N=33
Edema peripheral	9 (28.1)	0
Pyrexia	8 (25.0)	1 (3.1)
Anemia	7 (21.9)	3 (9.4)
Decreased appetite	7 (21.9)	1 (3.1)
Dyspepsia	7 (21.9)	0
Back pain	6 (18.8)	1 (3.1)
Diarrhea	6 (18.8)	1 (3.1)
Dyspnea	6 (18.8)	2 (6.3)
Increased blood bilirubin	5 (15.6)	1 (3.1)
Cough	5 (15.6)	0
Respiratory tract infection	5 (15.6)	1 (3.1)
Abdominal pain upper	4 (12.5)	0
Fatigue	4 (12.5)	0
Abdominal pain	3 (9.4)	1 (3.1)
Pulmonary embolism	3 (9.4)	3 (9.4)
Urinary tract infection	3 (9.4)	0
Vitamin k decreased	3 (9.4)	1 (3.1)
Blood albumin decreased	2 (6.3)	1 (3.1)
Candida infection	2 (6.3)	0
Depression	2 (6.3)	0
Headache	2 (6.3)	0
Hypotension	2 (6.3)	1 (3.1)
Lymphocyte count decreased	2 (6.3)	1 (3.1)
Rash	2 (6.3)	0
Vertigo	2 (6.3)	0
Weight decreased	2 (6.3)	0

Only adverse events occurring during treatment or within 30 days of the last dose of study treatment are reported.

FIGURES LEGENDS

Figure 1 Study schema

BID, twice daily; C, cycle; D, day; DDI, drug-drug interaction; PK, pharmacokinetics; PM, post morning

Figure 2 Geometric mean and arithmetic mean (SD) concentration-time profiles

1. Digoxin with and without capmatinib
2. Rosuvastatin with and without capmatinib



*: Day 11 capmatinib morning dose will be administered after PK sampling.
#The second 400 mg dose of capmatinib was to be given approximately 12 hours post morning dose of capmatinib

a. Digoxin with and without capmatinib



b. Rosuvastatin with and without capmatinib